Alnylam Pharmaceuticals (ALNY) Gross Margin (2018 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Gross Margin of 82.22% for Q1 2026, up 8.76% on a QoQ basis from 75.6% in Q4 2025, and down 597.0% year-over-year from 16.54% in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Gross Margin (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Gross Margin history runs 9 years deep, the most recent figure standing at 82.22% for Q1 2026.
- Quarterly Gross Margin fell 597.0% year-over-year to 82.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.0% (down 528.0% YoY) and the FY2025 annual result came in at 81.77%, down 460.0% from the prior year.
- Gross Margin was 82.22% for Q1 2026 at Alnylam Pharmaceuticals, up from 75.6% in the prior quarter.
- Across five years, Gross Margin topped out at 89.8% in Q2 2024 and bottomed at 75.6% in Q4 2025.
- A 5-year average of 84.68% and a median of 84.86% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin slumped 849 bps — and 2024, when it jumped 1344 bps.
- Alnylam Pharmaceuticals' Gross Margin stood at 86.22% in 2022, then retreated by 3 bps to 83.63% in 2023, then dropped by 1 bps to 82.69% in 2024, then retreated by 9 bps to 75.6% in 2025, then increased by 9 bps to 82.22% in 2026.
- Business Quant data shows ALNY's Gross Margin at 82.22% in Q1 2026, 75.6% in Q4 2025, and 84.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 90.68% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 82.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.22% |
| Dec 31, 2025 | 75.60% |
| Sep 30, 2025 | 84.21% |
| Jun 30, 2025 | 81.64% |
| Mar 31, 2025 | 88.19% |
| Dec 31, 2024 | 82.69% |
| Sep 30, 2024 | 83.63% |
| Jun 30, 2024 | 89.80% |
| Mar 31, 2024 | 88.95% |
| Dec 31, 2023 | 83.63% |
| Sep 30, 2023 | 89.41% |
| Jun 30, 2023 | 76.37% |
| Mar 31, 2023 | 87.02% |
| Dec 31, 2022 | 86.22% |
| Sep 30, 2022 | 86.19% |
| Jun 30, 2022 | 84.86% |
| Mar 31, 2022 | 89.00% |
| Dec 31, 2021 | 86.99% |
| Sep 30, 2021 | 85.03% |
| Jun 30, 2021 | 86.28% |